Semaglutide works as a medical tool that supports health goals rather than replacing fundamental lifestyle practices
On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
Used a specific mobile phase to dissolve the liposomes completely prior to injection, ensuring total drug quantification
Efficacy: the biggest uncertainty One of the biggest unanswered questions around oral GLP-1s is not convenience or appeal, but effectiveness
HUADONG MEDICINE, via its subsidiary Hangzhou Zhongmei HuaDong Pharmaceutical CO
Both Wegovy forms are made with semaglutide